Document Detail

Bile acid therapy and markers of immune-mediated damage in primary biliary cirrhosis.
MedLine Citation:
PMID:  9058624     Owner:  NLM     Status:  MEDLINE    
In primary biliary cirrhosis (PBC), liver damage results from both immune- and bile acid-mediated mechanisms. Therapies directed against the former have been either ineffective or toxic, while bile salt therapy is well tolerated but of uncertain long-term benefit. Because of slow disease progression, there is a need for surrogate markers of long-term efficacy. Candidates include markers of immune activation, such as soluble intercellular adhesion molecule-1 (sICAM-1) which shows promise in this respect. Using this marker, evidence has been presented to suggest an additive effect of the combination of ursodeoxycholic acid (UDCA) with azathioprine and prednisone in a short-term trial in PBC.
J S de Caestecker
Related Documents :
520764 - Conversion of 7-ketolithocholic acid to ursodeoxycholic acid by human intestinal anaero...
7399224 - Physical-chemical properties of chenodeoxycholic acid and ursodeoxycholic acid.
24877124 - The role of uric acid in kidney fibrosis: experimental evidences for the causal relatio...
7897324 - New 6-substituted bile acids: physico-chemical and biological properties of 6 alpha-met...
3880744 - Inhibition of the reductive activation of a valyl-trna synthetase from yeast by unsatur...
19815684 - Characteristic amino acid distribution around segments unique to allergens.
Publication Detail:
Type:  Comment; Journal Article    
Journal Detail:
Title:  European journal of gastroenterology & hepatology     Volume:  9     ISSN:  0954-691X     ISO Abbreviation:  Eur J Gastroenterol Hepatol     Publication Date:  1997 Feb 
Date Detail:
Created Date:  1997-03-25     Completed Date:  1997-03-25     Revised Date:  2009-10-16    
Medline Journal Info:
Nlm Unique ID:  9000874     Medline TA:  Eur J Gastroenterol Hepatol     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  145-7     Citation Subset:  IM    
Glenfield Hospital, Leicester, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Inflammatory Agents / therapeutic use*
Azathioprine / therapeutic use
Biological Markers / analysis
Cholagogues and Choleretics / therapeutic use*
Drug Therapy, Combination
Immunosuppressive Agents / therapeutic use*
Intercellular Adhesion Molecule-1 / analysis*
Liver Cirrhosis, Biliary / drug therapy*,  immunology*,  physiopathology
Prednisone / therapeutic use
Ursodeoxycholic Acid / therapeutic use*
Reg. No./Substance:
0/Anti-Inflammatory Agents; 0/Biological Markers; 0/Cholagogues and Choleretics; 0/Immunosuppressive Agents; 126547-89-5/Intercellular Adhesion Molecule-1; 128-13-2/Ursodeoxycholic Acid; 446-86-6/Azathioprine; 53-03-2/Prednisone
Comment On:
Eur J Gastroenterol Hepatol. 1997 Feb;9(2):155-61   [PMID:  9058626 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The role of surgery in the major early complications of severe acute pancreatitis.
Next Document:  Soluble intercellular adhesion molecule-1 in primary biliary cirrhosis: effect of ursodeoxycholic ac...